Stimulation of anti-tumor immunity by photodynamic therapy

References

• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin.58(2), 71–96 (2008).
   PubMed Web of Science ®Google Scholar
• Sheridan C. Fresh from the biologic pipeline – 2009. Nat. Biotechnol.28(4), 307–310 (2010).
   Google Scholar
• Simon R. Lost in translation: problems and pitfalls in translating laboratory observations to clinical utility. Eur. J. Cancer44(18), 2707–2713 (2008).
   PubMed Web of Science ®Google Scholar
• Wu X, Lee VC, Chevalier E, Hwang ST. Chemokine receptors as targets for cancer therapy. Curr. Pharm. Des.15(7), 742–757 (2009).
   PubMedGoogle Scholar
• Klastersky J. Adverse effects of the humanized antibodies used as cancer therapeutics. Curr. Opin Oncol.18(4), 316–320 (2006).
   PubMedGoogle Scholar
• Barrett A, Roques T, Small M, Smith RD. How much will Herceptin really cost? Br. Med. J.333(7578), 1118–1120 (2006).
   PubMed Web of Science ®Google Scholar
• La Porta CA. Mechanism of drug sensitivity and resistance in melanoma. Curr. Cancer Drug Targets9(3), 391–397 (2009).
   PubMed Web of Science ®Google Scholar
• Laconi E, Pani P, Farber E. The resistance phenotype in the development and treatment of cancer. Lancet Oncol.1, 235–241 (2000).
   PubMedGoogle Scholar
• Bianco R, Damiano V, Gelardi T, Daniele G, Ciardiello F, Tortora G. Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling. Curr. Pharm. Des.13(33), 3358–3367 (2007).
   Google Scholar
• Robertson CA, Evans DH, Abrahamse H. Photodynamic therapy (PDT): a short review on cellular mechanisms and cancer research applications for PDT. J. Photochem. Photobiol. B. Biol.96(1), 1–8 (2009).
   PubMed Web of Science ®Google Scholar
• Moan J, Peng Q. An outline of the hundred-year history of PDT. Anticancer Res.23(5A), 3591–3600 (2003).
   PubMed Web of Science ®Google Scholar
• Ogilby PR. Singlet oxygen: there is indeed something new under the sun. Chem. Soc. Rev.39(8), 3181–3209 (2010).
   PubMed Web of Science ®Google Scholar
• Robey RW, Steadman K, Polgar O, Bates SE. ABCG2-mediated transport of photosensitizers: potential impact on photodynamic therapy. Cancer Biol. Ther.4(2), 187–194 (2005).
   PubMed Web of Science ®Google Scholar
• Xue LY, Chiu SM, Oleinick NL. Atg7 deficiency increases resistance of MCF-7 human breast cancer cells to photodynamic therapy. Autophagy6(2), 248–255 (2010).
   PubMed Web of Science ®Google Scholar
• Detty MR, Gibson SL, Wagner SJ. Current clinical and preclinical photosensitizers for use in photodynamic therapy. J. Med. Chem.47(16), 3897–3915 (2004).
   PubMed Web of Science ®Google Scholar
• Boyle RW, Dolphin D. Structure and biodistribution relationships of photodynamic sensitizers. Photochem. Photobiol.64(3), 469–485 (1996).
   PubMed Web of Science ®Google Scholar
• Konan YN, Gurny R, Allemann E. State of the art in the delivery of photosensitizers for photodynamic therapy. J. Photochem. Photobiol. B. Biol.66(2), 89–106 (2002).
   PubMed Web of Science ®Google Scholar
• Oleinick NL, Morris RL, Belichenko I. The role of apoptosis in response to photodynamic therapy: what, where, why, and how. Photochem. Photobiol. Sci.1(1), 1–21 (2002).
   PubMed Web of Science ®Google Scholar
• Almeida RD, Manadas BJ, Carvalho AP, Duarte CB. Intracellular signaling mechanisms in photodynamic therapy. Biochim. Biophys. Acta1704(2), 59–86 (2004).
   PubMed Web of Science ®Google Scholar
• Granville DJ, McManus BM, Hunt DW. Photodynamic therapy: shedding light on the biochemical pathways regulating porphyrin-mediated cell death. Histol. Histopathol.16(1), 309–317 (2001).
   PubMed Web of Science ®Google Scholar
• Girotti AW. Photosensitized oxidation of membrane lipids: reaction pathways, cytotoxic effects, and cytoprotective mechanisms. J. Photochem. Photobiol. B. Biol.63(1–3), 103–113 (2001).
   PubMed Web of Science ®Google Scholar
• Kessel D, Reiners JJ Jr. Initiation of apoptosis and autophagy by the Bcl-2 antagonist HA14-1. Cancer Lett.249(2), 294–299 (2007).
   PubMed Web of Science ®Google Scholar
• Xue LY, Chiu SM, Azizuddin K, Joseph S, Oleinick NL. The death of human cancer cells following photodynamic therapy: apoptosis competence is necessary for Bcl-2 protection but not for induction of autophagy. Photochem. Photobiol.83(5), 1016–1023 (2007).
   PubMedGoogle Scholar
• Blum HF. Photodynamic Action and Diseases Caused by Light (No. 85). Reinhold Publishing Corporation, NY, USA, 239–250 (1941).
   Google Scholar
• Castano AP, Mroz P, Hamblin MR. Photodynamic therapy and anti-tumour immunity. Nat. Rev. Cancer6(7), 535–545 (2006).
   PubMed Web of Science ®Google Scholar
• Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J. Leukoc. Biol.81(1), 1–5 (2007).
   PubMed Web of Science ®Google Scholar
• Garg AD, Nowis D, Golab J, Agostinis P. Photodynamic therapy: illuminating the road from cell death towards anti-tumour immunity. Apoptosis15(9), 1050–1071 (2010).
   PubMed Web of Science ®Google Scholar
• Garg AD, Nowis D, Golab J, Vandenabeele P, Krysko DV, Agostinis P. Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. Biochim. Biophys. Acta1805(1), 53–71 (2010).
   PubMed Web of Science ®Google Scholar
• Seong SY, Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat. Rev. Immunol.4(6), 469–478 (2004).
   PubMed Web of Science ®Google Scholar
• Melcher A, Gough M, Todryk S, Vile R. Apoptosis or necrosis for tumor immunotherapy: what’s in a name? J. Mol. Med.77(12), 824–833 (1999).
   PubMedGoogle Scholar
• Melcher A, Todryk S, Hardwick N, Ford M, Jacobson M, Vile RG. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat. Med.4(5), 581–587 (1998).
   PubMed Web of Science ®Google Scholar
• Tesniere A, Panaretakis T, Kepp O et al. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ.15(1), 3–12 (2008).
   PubMed Web of Science ®Google Scholar
• Scheffer SR, Nave H, Korangy F et al. Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo. Int. J. Cancer.103(2), 205–211 (2003).
   PubMed Web of Science ®Google Scholar
• Goldszmid RS, Idoyaga J, Bravo AI, Steinman R, Mordoh J, Wainstok R. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma. J. Immunol.171(11), 5940–5947 (2003).
   PubMed Web of Science ®Google Scholar
• Kepp O, Tesniere A, Schlemmer F et al. Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis14(4), 364–375 (2009).
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Kroemer G. The immune response against dying tumor cells: avoid disaster, achieve cure. Cell Death Differ.15(1), 1–2 (2008).
   Google Scholar
• Korbelik M, Sun J, Cecic I. Photodynamic therapy-induced cell surface expression and release of heat shock proteins: relevance for tumor response. Cancer Res.65(3), 1018–1026 (2005).
   PubMed Web of Science ®Google Scholar
• Gomer CJ, Ryter SW, Ferrario A, Rucker N, Wong S, Fisher AM. Photodynamic therapy-mediated oxidative stress can induce expression of heat shock proteins. Cancer Res.56(10), 2355–2360 (1996).
   PubMed Web of Science ®Google Scholar
• Delves PJ, Roitt IM. The immune system. First of two parts. N. Engl. J. Med.343(1), 37–49 (2000).
   PubMed Web of Science ®Google Scholar
• Dougherty TJ, Gomer CJ, Henderson BW et al. Photodynamic therapy. J. Natl Cancer Inst.90(12), 889–905 (1998).
   PubMed Web of Science ®Google Scholar
• Korbelik M. Induction of tumor immunity by photodynamic therapy. J. Clin. Laser Med. Surg.14(5), 329–334 (1996).
   PubMedGoogle Scholar
• Gollnick SO, Evans SS, Baumann H et al. Role of cytokines in photodynamic therapy-induced local and systemic inflammation. Br. J. Cancer88(11), 1772–1779 (2003).
   PubMed Web of Science ®Google Scholar
• Korbelik M. PDT-associated host response and its role in the therapy outcome. Lasers Surg. Med.38(5), 500–508 (2006).
   Google Scholar
• Krosl G, Korbelik M, Dougherty GJ. Induction of immune cell infiltration into murine SCCVII tumour by photofrin-based photodynamic therapy. Br. J. Cancer71(3), 549–555 (1995).
   PubMed Web of Science ®Google Scholar
• Cecic I, Stott B, Korbelik M. Acute phase response-associated systemic neutrophil mobilization in mice bearing tumors treated by photodynamic therapy. Int. Immunopharmacol.6(8), 1259–1266 (2006).
   PubMed Web of Science ®Google Scholar
• Korbelik M, Cecic I. Complement activation cascade and its regulation: relevance for the response of solid tumors to photodynamic therapy. J. Photochem. Photobiol. B. Biol.93(1), 53–59 (2008).
   PubMed Web of Science ®Google Scholar
• Cecic I, Korbelik M. Deposition of complement proteins on cells treated by photodynamic therapy in vitro. J. Environ. Pathol. Toxicol. Oncol.25(1–2), 189–203 (2006).
   PubMed Web of Science ®Google Scholar
• Cecic I, Sun J, Korbelik M. Role of complement anaphylatoxin C3a in photodynamic therapy-elicited engagement of host neutrophils and other immune cells. Photochem. Photobiol.82(2), 558–562 (2006).
   Google Scholar
• Stott B, Korbelik M. Activation of complement C3, C5, and C9 genes in tumors treated by photodynamic therapy. Cancer Immunol. Immunother.56(5), 649–658 (2007).
   Google Scholar
• Cecic I, Korbelik M. Mediators of peripheral blood neutrophilia induced by photodynamic therapy of solid tumors. Cancer Lett.183(1), 43–51 (2002).
   PubMed Web of Science ®Google Scholar
• Korbelik M, Cecic I, Merchant S, Sun J. Acute phase response induction by cancer treatment with photodynamic therapy. Int. J. Cancer122(6), 1411–1417 (2008).
   Google Scholar
• Taylor PR, Martinez-Pomares L, Stacey M, Lin HH, Brown GD, Gordon S. Macrophage receptors and immune recognition. Annu. Rev. Immunol.23, 901–944 (2005).
   PubMed Web of Science ®Google Scholar
• Steubing RW, Yeturu S, Tuccillo A, Sun CH, Berns MW. Activation of macrophages by Photofrin II during photodynamic therapy. J. Photochem. Photobiol. B. Biol.10(1–2), 133–145 (1991).
   PubMed Web of Science ®Google Scholar
• Evans S, Matthews W, Perry R, Fraker D, Norton J, Pass HI. Effect of photodynamic therapy on tumor necrosis factor production by murine macrophages. J. Natl Cancer Inst.82(1), 34–39 (1990).
   PubMed Web of Science ®Google Scholar
• Yamamoto N, Homma S, Sery TW, Donoso LA, Hoober JK. Photodynamic immunopotentiation: in vitro activation of macrophages by treatment of mouse peritoneal cells with haematoporphyrin derivative and light. Eur. J. Cancer27(4), 467–471 (1991).
   Google Scholar
• Yamamoto N, Naraparaju VR. Immunotherapy of BALB/c mice bearing Ehrlich ascites tumor with vitamin D-binding protein-derived macrophage activating factor. Cancer Res.57(11), 2187–2192 (1997).
   PubMed Web of Science ®Google Scholar
• Korbelik M, Krosl G. Enhanced macrophage cytotoxicity against tumor cells treated with photodynamic therapy. Photochem. Photobiol.60(5), 497–502 (1994).
   PubMed Web of Science ®Google Scholar
• Marshall JF, Chan WS, Hart IR. Effect of photodynamic therapy on anti-tumor immune defenses: comparison of the photosensitizers hematoporphyrin derivative and chloro-aluminum sulfonated phthalocyanine. Photochem. Photobiol.49(5), 627–632 (1989).
   PubMed Web of Science ®Google Scholar
• Krosl G, Korbelik M, Krosl J, Dougherty GJ. Potentiation of photodynamic therapy-elicited antitumor response by localized treatment with granulocyte-macrophage colony-stimulating factor. Cancer Res.56(14), 3281–3286 (1996).
   PubMed Web of Science ®Google Scholar
• Delves PJ, Roitt IM. The immune system. N. Engl. J. Med.343, 37–49 (2000).
   PubMed Web of Science ®Google Scholar
• Henderson BW, Gollnick SO, Snyder JW et al. Choice of oxygen-conserving treatment regimen determines the inflammatory response and outcome of photodynamic therapy of tumors. Cancer Res.64(6), 2120–2126 (2004).
   PubMed Web of Science ®Google Scholar
• Kousis PC, Henderson BW, Maier PG, Gollnick SO. Photodynamic therapy enhancement of antitumor immunity is regulated by neutrophils. Cancer Res.67(21), 10501–10510 (2007).
   PubMed Web of Science ®Google Scholar
• Sluiter W, de Vree WJ, Pietersma A, Koster JF. Prevention of late lumen loss after coronary angioplasty by photodynamic therapy: role of activated neutrophils. Mol. Cell. Biochem.157(1–2), 233–238 (1996).
   Google Scholar
• de Vree WJ, Fontijne-Dorsman AN, Koster JF, Sluiter W. Photodynamic treatment of human endothelial cells promotes the adherence of neutrophils in vitro. Br. J. Cancer73(11), 1335–1340 (1996).
   Google Scholar
• Volanti C, Gloire G, Vanderplasschen A, Jacobs N, Habraken Y, Piette J. Downregulation of ICAM-1 and VCAM-1 expression in endothelial cells treated by photodynamic therapy. Oncogene23(53), 8649–8658 (2004).
   PubMed Web of Science ®Google Scholar
• de Vree WJ, Essers MC, de Bruijn HS, Star WM, Koster JF, Sluiter W. Evidence for an important role of neutrophils in the efficacy of photodynamic therapy in vivo. Cancer Res.56(13), 2908–2911 (1996).
   PubMed Web of Science ®Google Scholar
• Sun J, Cecic I, Parkins CS, Korbelik M. Neutrophils as inflammatory and immune effectors in photodynamic therapy-treated mouse SCCVII tumours. Photochem. Photobiol. Sci.1(9), 690–695 (2002).
   Google Scholar
• Cecic I, Parkins CS, Korbelik M. Induction of systemic neutrophil response in mice by photodynamic therapy of solid tumors. Photochem. Photobiol.74(5), 712–720 (2001).
   PubMed Web of Science ®Google Scholar
• de Bruijn HS, Sluiter W, van der Ploeg-van den Heuvel A, Sterenborg HJ, Robinson DJ. Evidence for a bystander role of neutrophils in the response to systemic 5-aminolevulinic acid-based photodynamic therapy. Photodermatol. Photoimmunol. Photomed.22(5), 238–246 (2006).
   Google Scholar
• Kabingu E, Vaughan L, Owczarczak B, Ramsey KD, Gollnick SO. CD8+ T cell-mediated control of distant tumours following local photodynamic therapy is independent of CD4+ T cells and dependent on natural killer cells. Br. J. Cancer96(12), 1839–1848 (2007).
   PubMed Web of Science ®Google Scholar
• Adams S, O’Neill DW, Bhardwaj N. Recent advances in dendritic cell biology. J. Clin. Immunol.25(3), 177–188 (2005).
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Chen HL, Girgis KR et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med.2(10), 1096–1103 (1996).
   PubMed Web of Science ®Google Scholar
• Yenari MA, Liu J, Zheng Z, Vexler ZS, Lee JE, Giffard RG. Antiapoptotic and anti-inflammatory mechanisms of heat-shock protein protection. Ann. NY Acad. Sci.1053, 74–83 (2005).
   PubMed Web of Science ®Google Scholar
• Todryk S, Melcher AA, Hardwick N et al. Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake. J. Immunol.163(3), 1398–1408 (1999).
   PubMed Web of Science ®Google Scholar
• Korbelik M, Sun J. Photodynamic therapy-generated vaccine for cancer therapy. Cancer Immunol. Immunother.55(8), 900–909 (2006).
   PubMed Web of Science ®Google Scholar
• Canti G, Lattuada D, Nicolin A, Taroni P, Valentini G, Cubeddu R. Antitumor immunity induced by photodynamic therapy with aluminum disulfonated phthalocyanines and laser light. Anticancer Drugs.5(4), 443–447 (1994).
   PubMed Web of Science ®Google Scholar
• Korbelik M, Krosl G, Krosl J, Dougherty GJ. The role of host lymphoid populations in the response of mouse EMT6 tumor to photodynamic therapy. Cancer Res.56(24), 5647–5652 (1996).
   PubMed Web of Science ®Google Scholar
• Korbelik M, Dougherty GJ. Photodynamic therapy-mediated immune response against subcutaneous mouse tumors. Cancer Res.59(8), 1941–1946 (1999).
   PubMed Web of Science ®Google Scholar
• Hendrzak-Henion JA, Knisely TL, Cincotta L, Cincotta E, Cincotta AH. Role of the immune system in mediating the antitumor effect of benzophenothiazine photodynamic therapy. Photochem. Photobiol.69(5), 575–581 (1999).
   PubMed Web of Science ®Google Scholar
• Van den Eynde BJ, van der Bruggen P. T cell defined tumor antigens. Curr. Opin. Immunol.9(5), 684–693 (1997).
   PubMed Web of Science ®Google Scholar
• Van den Eynde B, Lethe B, Van Pel A, De Plaen E, Boon T. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J. Exp. Med.173(6), 1373–1384 (1991).
   PubMed Web of Science ®Google Scholar
• Van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J. Exp. Med.182(3), 689–698 (1995).
   PubMed Web of Science ®Google Scholar
• van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science254(5038), 1643–1647 (1991).
   PubMed Web of Science ®Google Scholar
• Gaugler B, Van den Eynde B, van der Bruggen P et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med.179(3), 921–930 (1994).
   PubMed Web of Science ®Google Scholar
• Traversari C, van der Bruggen P, Luescher IF et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med.176(5), 1453–1457 (1992).
   PubMed Web of Science ®Google Scholar
• Coulie PG, Brichard V, Van Pel A et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med.180(1), 35–42 (1994).
   PubMed Web of Science ®Google Scholar
• Brichard V, Van Pel A, Wolfel T et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med.178(2), 489–495 (1993).
   PubMed Web of Science ®Google Scholar
• Bakker AB, Schreurs MW, de Boer AJ et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. Exp. Med.179(3), 1005–1009 (1994).
   PubMed Web of Science ®Google Scholar
• Coulie PG, Lehmann F, Lethe B et al. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc. Natl Acad. Sci. USA92(17), 7976–7980 (1995).
   PubMed Web of Science ®Google Scholar
• Mandelboim O, Berke G, Fridkin M, Feldman M, Eisenstein M, Eisenbach L. CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma. Nature369(6475), 67–71 (1994).
   Google Scholar
• Monach PA, Meredith SC, Siegel CT, Schreiber H. A unique tumor antigen produced by a single amino acid substitution. Immunity2(1), 45–59 (1995).
   PubMed Web of Science ®Google Scholar
• Robbins PF, El-Gamil M, Li YF et al. A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med.183(3), 1185–1192 (1996).
   PubMed Web of Science ®Google Scholar
• Dubey P, Hendrickson RC, Meredith SC et al. The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68. J. Exp. Med.185(4), 695–705 (1997).
   Google Scholar
• Wang M, Bronte V, Chen PW et al. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J. Immunol.154(9), 4685–4692 (1995).
   PubMed Web of Science ®Google Scholar
• McCabe BJ, Irvine KR, Nishimura MI et al. Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses. Cancer Res.55(8), 1741–1747 (1995).
   PubMed Web of Science ®Google Scholar
• Marzo AL, Lake RA, Robinson BW, Scott B. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. Cancer Res.59(5), 1071–1079 (1999).
   PubMed Web of Science ®Google Scholar
• Ramarathinam L, Sarma S, Maric M et al. Multiple lineages of tumors express a common tumor antigen, P1A, but they are not cross-protected. J. Immunol.155(11), 5323–5329 (1995).
   PubMed Web of Science ®Google Scholar
• Uyttenhove C, Godfraind C, Lethe B et al. The expression of mouse gene P1A in testis does not prevent safe induction of cytolytic T cells against a P1A-encoded tumor antigen. Int. J. Cancer.70(3), 349–356 (1997).
   Google Scholar
• Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat. Rev. Cancer7(1), 11–22 (2007).
   PubMed Web of Science ®Google Scholar
• Castano AP, Liu Q, Hamblin MR. A green fluorescent protein-expressing murine tumour but not its wild-type counterpart is cured by photodynamic therapy. Br. J. Cancer94(3), 391–397 (2006).
   PubMed Web of Science ®Google Scholar
• Mroz P, Szokalska A, Wu MX, Hamblin M. Photodynamic therapy of tumors can lead to development of systemic antigen-specific immune response. PLoS ONE (2011) (In Press).
   Google Scholar
• Abdel-Hady ES, Martin-Hirsch P, Duggan-Keen M et al. Immunological and viral factors associated with the response of vulval intraepithelial neoplasia to photodynamic therapy. Cancer Res.61(1), 192–196 (2001).
   PubMed Web of Science ®Google Scholar
• Kabingu E, Oseroff AR, Wilding GE, Gollnick SO. Enhanced systemic immune reactivity to a Basal cell carcinoma associated antigen following photodynamic therapy. Clin. Cancer Res.15(13), 4460–4466 (2009).
   PubMed Web of Science ®Google Scholar
• Gershon RK, Cohen P, Hencin R, Leibhaber SA. Suppressor T cells. J. Immunol.108, 586–590 (1972).
   PubMed Web of Science ®Google Scholar
• Dejaco C, Duftner C, Grubeck-Loebenstein B, Schirmer M. Imbalance of regulatory T cells in human autoimmune diseases. Immunology117(3), 289–300 (2006).
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Sakaguchi S. Regulatory T cells in immune surveillance and treatment of cancer. Semin. Cancer Biol.16(2), 115–123 (2006).
   PubMed Web of Science ®Google Scholar
• Antony PA, Restifo NP. CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2. J. Immunother.28(2), 120–128 (2005).
   PubMed Web of Science ®Google Scholar
• Fontenot JD, Rudensky AY. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat. Immunol.6(4), 331–337 (2005).
   PubMed Web of Science ®Google Scholar
• Scotto L, Naiyer AJ, Galluzzo S et al. Overlap between molecular markers expressed by naturally occurring CD4+CD25+ regulatory T cells and antigen specific CD4+CD25+ and CD8+CD28- T suppressor cells. Hum. Immunol.65(11), 1297–1306 (2004).
   PubMed Web of Science ®Google Scholar
• Albers AE, Ferris RL, Kim GG, Chikamatsu K, DeLeo AB, Whiteside TL. Immune responses to p53 in patients with cancer: enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites. Cancer Immunol. Immunother.54(11), 1072–1081 (2005).
   PubMed Web of Science ®Google Scholar
• Ziegler SF. FOXP3: of mice and men. Annu. Rev. Immunol.24, 209–226 (2006).
   PubMed Web of Science ®Google Scholar
• Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol.6(4), 295–307 (2006).
   PubMed Web of Science ®Google Scholar
• Curotto de Lafaille MA, Lino AC, Kutchukhidze N, Lafaille JJ. CD25- T cells generate CD25+Foxp3+ regulatory T cells by peripheral expansion. J. Immunol.173(12), 7259–7268 (2004).
   PubMed Web of Science ®Google Scholar
• Chen W, Jin W, Hardegen N et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3. J. Exp. Med.198(12), 1875–1886 (2003).
   PubMed Web of Science ®Google Scholar
• Bluestone JA, Tang Q. How do CD4+CD25+ regulatory T cells control autoimmunity? Curr. Opin. Immunol.17(6), 638–642 (2005).
   PubMed Web of Science ®Google Scholar
• Tang Q, Boden EK, Henriksen KJ, Bour-Jordan H, Bi M, Bluestone JA. Distinct roles of CTLA-4 and TGF-β in CD4+CD25+ regulatory T cell function. Eur. J. Immunol.34(11), 2996–3005 (2004).
   PubMed Web of Science ®Google Scholar
• Stephens GL, McHugh RS, Whitters MJ et al. Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+CD25+ T cells. J. Immunol.173(8), 5008–5020 (2004).
   PubMed Web of Science ®Google Scholar
• Marie JC, Letterio JJ, Gavin M, Rudensky AY. TGF-β1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J. Exp. Med.201(7), 1061–1067 (2005).
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Puig PE, Roux S et al. Tumor cells convert immature myeloid dendritic cells into TGF-β-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J. Exp. Med.202(7), 919–929 (2005).
   PubMed Web of Science ®Google Scholar
• Veldhoen M, Moncrieffe H, Hocking RJ, Atkins CJ, Stockinger B. Modulation of dendritic cell function by naive and regulatory CD4+ T cells. J. Immunol.176(10), 6202–6210 (2006).
   PubMed Web of Science ®Google Scholar
• Rudensky AY, Campbell DJ. In vivo sites and cellular mechanisms of T reg cell-mediated suppression. J. Exp. Med.203(3), 489–492 (2006).
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Larmonier N, Schmitt E et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol.34(2), 336–344 (2004).
   PubMed Web of Science ®Google Scholar
• Rollinghoff M, Starzinski-Powitz A, Pfizenmaier K, Wagner H. Cyclophosphamide-sensitive T lymphocytes suppress the in vivo generation of antigen-specific cytotoxic T lymphocytes. J. Exp. Med.145(2), 455–459 (1977).
   PubMed Web of Science ®Google Scholar
• Glaser M. Regulation of specific cell-mediated cytotoxic response against SV40-induced tumor associated antigens by depletion of suppressor T cells with cyclophosphamide in mice. J. Exp. Med.149(3), 774–779 (1979).
   PubMed Web of Science ®Google Scholar
• Berendt MJ, North RJ. T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. J. Exp. Med.151(1), 69–80 (1980).
   PubMed Web of Science ®Google Scholar
• Loeffler M, Kruger JA, Reisfeld RA. Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase. Cancer Res.65(12), 5027–5030 (2005).
   PubMed Web of Science ®Google Scholar
• Castano AP, Hamblin MR. Anti-tumor immunity generated by photodynamic therapy in a metastatic murine tumor model. Proc. SPIE5695, 7–16 (2005).
   Google Scholar
• Muzio M, Mantovani A. Toll-like receptors. Microbes Infect.2(3), 251–255 (2000).
   PubMed Web of Science ®Google Scholar
• Oshiumi H, Matsuo A, Matsumoto M, Seya T. Pan-vertebrate Toll-like receptors during evolution. Curr. Genomics9(7), 488–493 (2008).
   PubMed Web of Science ®Google Scholar
• Armant MA, Fenton MJ. Toll-like receptors: a family of pattern-recognition receptors in mammals. Genome Biol.3(8), reviews3011.1–reviews3011.6 (2002).
   Google Scholar
• van Kooyk Y. C-type lectins on dendritic cells: key modulators for the induction of immune responses. Biochem. Soc. Trans.36(Pt 6), 1478–1481 (2008).
   PubMed Web of Science ®Google Scholar
• Cambi A, Koopman M, Figdor CG. How C-type lectins detect pathogens. Cell Microbiol.7(4), 481–488 (2005).
   PubMed Web of Science ®Google Scholar
• Chen WR, Korbelik M, Bartels KE, Liu H, Sun J, Nordquist RE. Enhancement of laser cancer treatment by a chitosan-derived immunoadjuvant. Photochem. Photobiol.81(1), 190–195 (2005).
   PubMed Web of Science ®Google Scholar
• Krosl G, Korbelik M. Potentiation of photodynamic therapy by immunotherapy: the effect of schizophyllan (SPG). Cancer Lett.84(1), 43–49 (1994).
   Google Scholar
• Korbelik M, Sun J, Cecic I, Serrano K. Adjuvant treatment for complement activation increases the effectiveness of photodynamic therapy of solid tumors. Photochem. Photobiol. Sci.3(8), 812–816 (2004).
   Google Scholar
• Bellnier DA. Potentiation of photodynamic therapy in mice with recombinant human tumor necrosis factor-α. J. Photochem. Photobiol. B. Biol.8(2), 203–210 (1991).
   PubMedGoogle Scholar
• Korbelik M, Naraparaju VR, Yamamoto N. Macrophage-directed immunotherapy as adjuvant to photodynamic therapy of cancer. Br. J. Cancer75(2), 202–207 (1997).
   PubMed Web of Science ®Google Scholar
• Golab J, Wilczynski G, Zagozdzon R et al. Potentiation of the anti-tumour effects of Photofrin-based photodynamic therapy by localized treatment with G-CSF. Br. J. Cancer82(8), 1485–1491 (2000).
   PubMed Web of Science ®Google Scholar
• Korbelik M, Cooper PD. Potentiation of photodynamic therapy of cancer by complement: the effect of γ-inulin. Br. J. Cancer96(1), 67–72 (2007).
   PubMed Web of Science ®Google Scholar
• Weiner LM, Surana R, Murray J. Vaccine prevention of cancer: can endogenous antigens be targeted? Cancer Prev. Res.3(4), 410–415 (2010).
   PubMedGoogle Scholar
• Critchfield JM, Racke MK, Zuniga-Pflucker JC et al. T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science263(5150), 1139–1143 (1994).
   PubMed Web of Science ®Google Scholar
• Gollnick SO, Vaughan L, Henderson BW. Generation of effective antitumor vaccines using photodynamic therapy. Cancer Res.62(6), 1604–1608 (2002).
   PubMed Web of Science ®Google Scholar
• Sgambato A, Cittadini A. Inflammation and cancer: a multifaceted link. Eur. Rev. Med. Pharmacol. Sci.14(4), 263–268 (2010).
   Google Scholar
• Thong PS, Ong KW, Goh NS et al. Photodynamic-therapy-activated immune response against distant untreated tumours in recurrent angiosarcoma. Lancet Oncol.8(10), 950–952 (2007).
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Kepp O, Senovilla L, Menger L, Chaput N, Kroemer G. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin. Cancer Res.16(12), 3100–3104 (2010).
   PubMed Web of Science ®Google Scholar
• Spisek R, Dhodapkar MV. Towards a better way to die with chemotherapy: role of heat shock protein exposure on dying tumor cells. Cell Cycle6(16), 1962–1965 (2007).
   PubMed Web of Science ®Google Scholar
• Tang D, Kang R, Zeh HJ 3rd, Lotze MT. High-mobility group box 1 and cancer. Biochim. Biophys. Acta1799(1–2), 131–140 (2010).
   PubMed Web of Science ®Google Scholar
• Martins I, Tesniere A, Kepp O et al. Chemotherapy induces ATP release from tumor cells. Cell Cycle8(22), 3723–3728 (2009).
   PubMed Web of Science ®Google Scholar
• Donato R. RAGE: a single receptor for several ligands and different cellular responses: the case of certain S100 proteins. Curr. Mol. Med.7(8), 711–724 (2007).
   PubMed Web of Science ®Google Scholar
• Yamasaki S, Ishikawa E, Sakuma M, Hara H, Ogata K, Saito T. Mincle is an ITAM-coupled activating receptor that senses damaged cells. Nat. Immunol.9(10), 1179–1188 (2008).
   PubMed Web of Science ®Google Scholar
• Horino K, Nishiura H, Ohsako T et al. A monocyte chemotactic factor, S19 ribosomal protein dimer, in phagocytic clearance of apoptotic cells. Lab. Invest.78(5), 603–617 (1998).
   PubMed Web of Science ®Google Scholar
• Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature425(6957), 516–521 (2003).
   PubMed Web of Science ®Google Scholar
• Uehara M, Sano K, Wang ZL, Sekine J, Ikeda H, Inokuchi T. Enhancement of the photodynamic antitumor effect by streptococcal preparation OK-432 in the mouse carcinoma. Cancer Immunol. Immunother.49(8), 401–409 (2000).
   PubMed Web of Science ®Google Scholar
• Castano AP, Hamblin MR. Enhancing photodynamic therapy of a metastatic mouse breast cancer by immune stimulation. In: Biophotonics and Immune Responses. San Jose: The International Society for Optical Engineering, WA, USA (2006).
   Google Scholar
• Korbelik M, Cecic I. Enhancement of tumour response to photodynamic therapy by adjuvant mycobacterium cell-wall treatment. J. Photochem. Photobiol. B. Biol.44(2), 151–158 (1998).
   Google Scholar
• Korbelik M, Sun J, Posakony JJ. Interaction between photodynamic therapy and BCG immunotherapy responsible for the reduced recurrence of treated mouse tumors. Photochem. Photobiol.73(4), 403–409 (2001).
   Google Scholar
• Myers RC, Lau BH, Kunihira DY, Torrey RR, Woolley JL, Tosk J. Modulation of hematoporphyrin derivative-sensitized phototherapy with corynebacterium parvum in murine transitional cell carcinoma. Urology33(3), 230–235 (1989).
   PubMed Web of Science ®Google Scholar
• Winters U, Daayana S, Lear JT et al. Clinical and immunologic results of a Phase II trial of sequential imiquimod and photodynamic therapy for vulval intraepithelial neoplasia. Clin. Cancer Res.14(16), 5292–5299 (2008).
   PubMed Web of Science ®Google Scholar
• Seshadri M, Bellnier DA. The vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid improves the antitumor efficacy and shortens treatment time associated with Photochlor-sensitized photodynamic therapy in vivo. Photochem. Photobiol.85(1), 50–56 (2009).
   PubMed Web of Science ®Google Scholar
• Krosl G, Korbelik M, Krosl J, Dougherty GJ. Potentiation of photodynamic therapy-elicited antitumor response by localized treatment with granulocyte-macrophage colony-stimulating factor. Cancer Res.56(14), 3281–3286 (1996).
   PubMed Web of Science ®Google Scholar
• Castano AP, Mroz P, Wu MX, Hamblin MR. Photodynamic therapy plus low-dose cyclophosphamide generates antitumor immunity in a mouse model. Proc. Natl Acad. Sci. USA105(14), 5495–5500 (2008).
   PubMed Web of Science ®Google Scholar